Milagen, Inc.

Milagen spent over 25 years in research and development to find the best screening diagnostic option for the earlier detection of cancer and especially its recurrence. 

We developed and validated blood-based tests on thousands of patients for the earlier detection of the five major cancers that account for almost 50% of all cancer incidence (breast, colorectal, lung, prostate, and ovarian cancer). 

Our tests detect blood-secreted markers at the early development of cancer as well as its early recurrence. 

Our tests help patients and physicians to take preventive therapeutic measures and obtain better clinical outcomes.